Table 7.
Summary of cost and benefit in the additional scenario analysis
Cost(SG$) | QALYs | LYs | PFLYs | ICER (SG$/QALY) | |
---|---|---|---|---|---|
Independent model with parametric fittinga | |||||
Weilbull | |||||
PemCis | 76,679 | 1.54 | 2.38 | 0.66 | |
Afatinib | 92,486 | 1.66 | 2.55 | 1.10 | 129,416 |
Exponential | |||||
PemCis | 73,775 | 1.53 | 2.37 | 0.71 | |
Afatinib | 92,507 | 1.66 | 2.55 | 1.18 | 143,658 |
Log-normal | |||||
PemCis | 76,851 | 1.57 | 2.43 | 0.70 | |
Afatinib | 94,966 | 1.72 | 2.61 | 1.32 | 126,202 |
Log-logistic | |||||
PemCis | 76,046 | 1.57 | 2.43 | 0.73 | |
Afatinib | 94,764 | 1.71 | 2.60 | 1.34 | 133,627 |
Pricing scenariob | |||||
10% reduction | |||||
PemCis | 75,682 | 1.58 | 2.45 | 0.68 | |
Afatinib | 89,880 | 1.69 | 2.59 | 1.18 | 128,348 |
20% reduction | |||||
PemCis | 72,632 | 1.58 | 2.45 | 0.68 | |
Afatinib | 85,802 | 1.69 | 2.59 | 1.18 | 119,048 |
30% reduction | |||||
PemCis | 69,583 | 1.58 | 2.45 | 0.68 | |
Afatinib | 81,724 | 1.69 | 2.59 | 1.18 | 109,747 |
40% reduction | |||||
PemCis | 66,534 | 1.58 | 2.45 | 0.68 | |
Afatinib | 77,646 | 1.69 | 2.59 | 1.18 | 100,447 |
50% reduction | |||||
PemCis | 63,485 | 1.58 | 2.45 | 0.68 | |
Afatinib | 73,568 | 1.69 | 2.59 | 1.18 | 91,147 |
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, LY life year, PFLY progression-free life year, PemCis pemetrexed-cisplatin
aProgression-free and overall survival curves of both intervention arms extrapolated from Kaplan-Meier data from trial, with parametric curve fitting from time = 0 to tail-end
bPricing scenario with various discounting on the cost of afatinib. Afatinib was modelled in the first-line for the afatinib arm, and post-progression (second-line) for the PemCis arm, therefore the total cost of both arms reduced as a result of the reduction in selling price of afatinib